Fortis Capital Advisors LLC Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Fortis Capital Advisors LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 72.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,279 shares of the company's stock after selling 5,915 shares during the period. Fortis Capital Advisors LLC's holdings in Novo Nordisk A/S were worth $196,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Center for Financial Planning Inc. grew its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Albion Financial Group UT raised its holdings in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC boosted its position in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after acquiring an additional 243 shares during the last quarter. Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $46,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. BNP Paribas started coverage on shares of Novo Nordisk A/S in a research note on Tuesday. They issued an "underperform" rating for the company. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and an average target price of $135.00.

Novo Nordisk A/S Trading Down 7.1 %

Shares of NYSE:NVO traded down $4.47 on Thursday, hitting $58.41. 23,528,479 shares of the company's stock were exchanged, compared to its average volume of 8,747,341. The stock has a market capitalization of $262.12 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 12 month low of $57.28 and a 12 month high of $148.15. The business's 50 day simple moving average is $76.55 and its two-hundred day simple moving average is $92.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.